Norman Eansor
Patrimonio netto: 3 953 $ in data 30/09/2026
Patrimonio netto: 3 953 $ in data 30/09/2026
Norman David Eansor is currently Chairman at Marker Therapeutics, Inc. since 2022, Director at B-MoGen Biotechnologies, Inc., and President at Cyvek, Inc. Former positions include President-Bioproducts Business Unit at Cambrex Corp.
in 2005, President-Protein Sciences Segment at Bio-Techne Corp.
from 2018 to 2022, Vice President-Pharmaceutical Operations at R.P.
Scherer Corp., President-Bioscience Division at Thermo Fisher Scientific, Inc. from 2010 to 2013, Vice President-Operations at Cardinal Health Corp.
in 2000, and Senior Vice President-Development & MD at Novus Biologicals LLC from 2013 to 2015.
Education includes undergraduate studies at the University of Western Ontario and an MBA from the University of Windsor.
| Società | Data | Numero di azioni | Valutazione | Data di valutazione |
|---|---|---|---|---|
| 01/03/2026 | 3.694 ( 0,02% ) | 3 953 $ | 30/09/2026 |
| Società | Posizione | Inizio |
|---|---|---|
| MARKER THERAPEUTICS, INC. | Presidente | 24/05/2022 |
B-MoGen Biotechnologies, Inc.
B-MoGen Biotechnologies, Inc. BiotechnologyHealth Technology Provides gene editing solutions for antibody validation, human disease research, gene transfer, and mitochondrial DNA editing | Direttore/Membro del Consiglio | - |
CyVek, Inc.
CyVek, Inc. BiotechnologyHealth Technology Engages in the development of a novel, platform technology for measuring analytes in biological samples | Presidente | - |
| Società | Posizione | Fine |
|---|---|---|
| BIO-TECHNE CORPORATION | Corporate Officer/Principal | 03/01/2022 |
Novus Biologicals LLC
Novus Biologicals LLC Pharmaceuticals: MajorHealth Technology Develops and markets antibodies for scientific researchers | Corporate Officer/Principal | 01/01/2015 |
| THERMO FISHER SCIENTIFIC, INC. | Corporate Officer/Principal | 01/01/2013 |
| CAMBREX CORPORATION | Corporate Officer/Principal | 01/01/2005 |
Cardinal Health Corp.
Cardinal Health Corp. Medical DistributorsDistribution Services Manufactures and distributes hospital equipment | Direttore operativo | 01/01/2000 |
Attive
Inattive
Società nel listino
Aziende private
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
| Aziende private | 11 |
|---|---|
Cambrex Corp.
Cambrex Corp. Pharmaceuticals: GenericHealth Technology Develops and manufactures drug substances | Health Technology |
R.P. Scherer Corp.
R.P. Scherer Corp. Pharmaceuticals: MajorHealth Technology Develops and manufactures oral drug delivery systems | Health Technology |
Bio-Techne Corp.
Bio-Techne Corp. BiotechnologyHealth Technology Manufactures and sells biological products | Health Technology |
Marker Therapeutics, Inc.
Marker Therapeutics, Inc. BiotechnologyHealth Technology Develops and commercializes cell based immune therapeutics and vaccines for cancer treatment | Health Technology |
CyVek, Inc.
CyVek, Inc. BiotechnologyHealth Technology Engages in the development of a novel, platform technology for measuring analytes in biological samples | Health Technology |
University of Western Ontario
University of Western Ontario Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
University of Windsor
University of Windsor Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Thermo Fisher Scientific, Inc.
Thermo Fisher Scientific, Inc. Medical SpecialtiesHealth Technology Develops, manufactures and markets analytical and environment monitoring instruments | Health Technology |
Novus Biologicals LLC
Novus Biologicals LLC Pharmaceuticals: MajorHealth Technology Develops and markets antibodies for scientific researchers | Health Technology |
Cardinal Health Corp.
Cardinal Health Corp. Medical DistributorsDistribution Services Manufactures and distributes hospital equipment | Distribution Services |
B-MoGen Biotechnologies, Inc.
B-MoGen Biotechnologies, Inc. BiotechnologyHealth Technology Provides gene editing solutions for antibody validation, human disease research, gene transfer, and mitochondrial DNA editing | Health Technology |
Seleziona la tua edizione
Tutte le informazioni finanziarie adattate in base al livello nazionale